Literature DB >> 3484676

Regulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in human leukemia cells by deoxycytidine 5'-triphosphate.

J O Liliemark, W Plunkett.   

Abstract

Cell cycle-specific fluctuations in the ability of human leukemic cells to phosphorylate 1-beta-D-arabinofuranosylcytosine (ara-C) to the toxic metabolite 1-beta-D-arabinofuranosylcytosine 5'-triphosphate (ara-CTP) was investigated in whole cells and in cell extracts. Exponentially growing CCRF-CEM cells were fractionated into populations enriched for G1 phase cells and S phase cells by centrifugal elutriation. The accumulation of ara-CTP by S phase-enriched cells was 50% greater than in G1-enriched cells. However, the ability of extracts of S phase-enriched cells to phosphorylate ara-C was twice that of G1 phase-enriched cell extracts. As cells passed from G1 to S phase, this disproportionality was significant. As demonstrated in other cell types, deoxycytidine 5'-triphosphate (dCTP) also potently inhibited ara-C phosphorylation in CCRF-CEM cell extracts (Ki = 5.9 microM). Deoxynucleotide pool levels determined by high pressure liquid chromatography showed a 5 microM dCTP concentration in G1-enriched cells, whereas S phase-enriched cells contained 15 microM dCTP. These findings suggest that the lack of proportionality between the accumulation of ara-CTP in whole cells and the increase of ara-C phosphorylation in extracts during the G1 to S phase transition may be caused by more stringent regulation of ara-C phosphorylation in whole cells by the concomitant increase in cellular dCTP concentrations. Because such regulation is unlikely to be observed in cell extracts, these results indicated that assays of ara-C phosphorylating activity in cell extracts represent upper limits for that function in whole cells. Such determinations may not reflect the regulated nature of the metabolic pathway.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484676

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.

Authors:  Xueyuan Cao; Amit K Mitra; Stanley Pounds; Kristine R Crews; Varsha Gandhi; William Plunkett; M Eileen Dolan; Christine Hartford; Susana Raimondi; Dario Campana; James Downing; Jeffrey E Rubnitz; Raul C Ribeiro; Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

2.  The MitoNEET Ligand NL-1 Mediates Antileukemic Activity in Drug-Resistant B-Cell Acute Lymphoblastic Leukemia.

Authors:  Werner J Geldenhuys; Rajesh R Nair; Debbie Piktel; Karen H Martin; Laura F Gibson
Journal:  J Pharmacol Exp Ther       Date:  2019-04-22       Impact factor: 4.030

3.  Arabinofuranosyl nucleosides induce common fragile sites.

Authors:  J C Leonard; R C Leonard; K H Thompson
Journal:  Hum Genet       Date:  1988-06       Impact factor: 4.132

Review 4.  Genetic factors influencing cytarabine therapy.

Authors:  Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2009-10       Impact factor: 2.533

5.  Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.

Authors:  V Gandhi; W Plunkett
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.

Authors:  I Hubeek; R W Stam; G J Peters; R Broekhuizen; J P P Meijerink; E R van Wering; B E S Gibson; U Creutzig; C M Zwaan; J Cloos; D J Kuik; R Pieters; G J L Kaspers
Journal:  Br J Cancer       Date:  2005-12-12       Impact factor: 7.640

7.  Enhancement of the cytotoxicity of cytosine arabinoside by interleukin-3.

Authors:  M Tanaka
Journal:  Jpn J Cancer Res       Date:  1992-02

8.  Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.

Authors:  Hai-Xia Cao; Chao-Feng Miao; Liang Yan; Ping Tang; Li-Rong Zhang; Ling Sun
Journal:  J Transl Med       Date:  2017-11-15       Impact factor: 5.531

9.  Enhancement of cytosine arabinoside cytotoxicity by granulocyte/macrophage colony-stimulating factor and granulocyte colony-stimulating factor in a human myeloblastic leukemia cell line.

Authors:  R Takauji; K Tohyama; T Ueda; T Nakamura
Journal:  Jpn J Cancer Res       Date:  1993-04

10.  Modulation of the effect of 1-beta-D-arabinofuranosylcytosine by 6-mercaptopurine in L1210 cells.

Authors:  Y Kawai; T Ueda; T Nakamura
Journal:  Jpn J Cancer Res       Date:  1994-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.